Breckenridge Pharmaceutical Inc, the US subsidiary of Spain-based Towa International, announced on Monday the launch of Pomalidomide Capsules, a generic version of Pomalyst by Celgene (now Bristol Myers Squibb), within the oncology therapeutic category.
The product was developed in partnership with NATCO Pharma Limited of India.
Pomalidomide Capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma.
The product is available in 1mg, 2mg, 3mg, and 4mg strengths and is distributed primarily through specialty pharmacies and clinics.
Pomalidomide Capsules are available only through a restricted programme called PS-Pomalidomide REMS.
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval